Takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes.
Provides PGS data analysis in a single framework.
We offer a comprehensive karyomapping solution:
A noninvasive prenatal test service that screens for multiple fetal chromosomal aneuploidies using a single maternal blood draw. The Verifi Prenatal Test screens for T21 (Down syndrome), T18 (Edwards syndrome), and T13 (Patau syndrome).
Comprehensive, IVD, in-lab aneuploidy screening solution providing reagents, instruments, and software for accurate NIPT results in 26 hours, available in select countries.
A comprehensive, cost-effective solution for identifying causal variants implicated in inherited cardiac conditions (ICCs). It detects 174 genes related to 17 ICCs, including most cardiomyopathies and arrhythmias.
Comprehensive panels targeting disease-associated regions of the exome with high analytical sensitivity and specificity.
Focuses on researching severe, recessive pediatric onset diseases.
Designed by international consortia to provide the most comprehensive coverage of cytogenetically relevant genes for cancer studies.
A 12-sample BeadChip array that enables analysis of genetic and structural variation in the human genome, such as duplications, deletions, amplifications, copy-neutral LOH, and mosaicism.
Desktop sequencer featuring a simple workflow, integrated data analysis software, and unmatched accuracy.
The first FDA-cleared platform for in vitro diagnostic (IVD) testing. It provides a research mode to generate accurate, reliable data.
The Verifi Prenatal Test was developed by, and its performance characteristics were determined by Verinata Health, Inc. a wholly owned subsidiary of Illumina, Inc. The VHI laboratory is CAP-accredited and certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. It has not been cleared or approved by the U.S. Food and Drug Administration.